Concepedia

Qingbei Zeng

QZ

26

Publications

618

Citations

16

H-Index

1994

Active since

Affiliations

Merck & Co., Inc., Rahway, NJ, USA (United States)(Current)

The Ohio State University

WuXi AppTec (China)

United States Military Academy

Ligand Pharmaceuticals (United States)

Qingbei Zeng is an author at Merck & Co., Inc., Rahway, NJ, USA (United States) specializing in pharmacology, drug discovery, and medicine.

Top concepts

Publications per year

1994–2018

26

Publications

26

Discovery and Evaluation of Clinical Candidate AZD3759, a Potent, Oral Active, Central Nervous System-Penetrant, Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor

Qingbei Zeng, Jiabing Wang, Ziqiang Cheng et al. · Journal of Medicinal Chemistry · 2015 · 148 citations · Full text

, , +17

I. Novel HCV NS5B polymerase inhibitors: Discovery of indole 2-carboxylic acids with C3-heterocycles

G. Anilkumar, Charles A. Lesburg, Oleg Selyutin et al. · Bioorganic & Medicinal Chemistry Letters · 2011 · 49 citations

, , +5

Structure–Activity Relationship (SAR) Development and Discovery of Potent Indole-Based Inhibitors of the Hepatitis C Virus (HCV) NS5B Polymerase

Kevin X. Chen, Bancha Vibulbhan, Weiying Yang et al. · Journal of Medicinal Chemistry · 2011 · 30 citations · Full text

, , +24

Discovery of silyl proline containing HCV NS5A inhibitors with pan-genotype activity: SAR development

Anilkumar G. Nair, Qingbei Zeng, Oleg Selyutin et al. · Bioorganic & Medicinal Chemistry Letters · 2016 · 27 citations · Full text

, , +8

A Novel Class of Highly Potent Irreversible Hepatitis C Virus NS5B Polymerase Inhibitors

Kevin X. Chen, Charles A. Lesburg, Bancha Vibulbhan et al. · Journal of Medicinal Chemistry · 2012 · 27 citations

, , +24

Rows per page

1–5 of 26